Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 23 05 2023
accepted: 20 07 2023
medline: 22 8 2023
pubmed: 21 8 2023
entrez: 21 8 2023
Statut: epublish

Résumé

Tumor-infiltrating lymphocytes (TILs) have predictive and prognostic value in breast cancer (BC) and exert a protective function against tumor growth, indicating that it is susceptible to treatment using adoptive cell transfer of TILs or T cell receptor (TCR)-based therapies. TCR can be used to identify naturally tumor-reactive T cells, but little is known about the differences in the TCR repertoires of CD4+ and CD8+ TILs. TCR high-throughput sequencing was performed using TILs derived from the initial cultures of 11 BC biopsies and expanded and sorted CD4+ and CD8+ TILs as well as using PBMCs from healthy donors expanded and sorted using the same methodology. Physicochemical TCR differences between T cell subsets were observed, as CD4+ TILs presented larger N(D)Nnt TRB sequences and with a higher usage of positively charged residues, although only the latest was also observed in peripheral T cells from healthy individuals. Moreover, in CD4+ TILs, a more restricted TCR repertoire with a higher abundance of similar sequences containing certain amino acid motifs was observed. Some differences between CD4+ and CD8+ TCRs were intrinsic to T cell subsets as can also be observed in peripheral T cells from healthy individuals, while other were only found in TILs samples and therefore may be tumor-driven. Notably, the higher similarity among CD4+ TCRs suggests a higher TCR promiscuity in this subset.

Identifiants

pubmed: 37600765
doi: 10.3389/fimmu.2023.1227766
pmc: PMC10436466
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1227766

Informations de copyright

Copyright © 2023 Aran, Lázaro, Marco, Molina, Abancó, Peg, Gión, Garrigós, Pérez-García, Cortés and Martí.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Clin Med Insights Oncol. 2016 Apr 05;10(Suppl 1):31-9
pubmed: 27081325
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Med. 2015 Aug;21(8):914-921
pubmed: 26193344
Front Immunol. 2019 Feb 26;10:299
pubmed: 30863407
Front Immunol. 2020 Jan 09;10:2985
pubmed: 31993050
Nat Genet. 2016 Sep;48(9):995-1002
pubmed: 27479906
Clin Cancer Res. 2020 Aug 15;26(16):4289-4301
pubmed: 32303540
Bioinformatics. 2017 Sep 15;33(18):2924-2929
pubmed: 28481982
Mol Ther. 2011 Mar;19(3):620-6
pubmed: 21157437
Diabetes. 2008 Aug;57(8):2099-106
pubmed: 18492786
J Leukoc Biol. 2016 Mar;99(3):505-13
pubmed: 26394815
Cell. 2020 Nov 25;183(5):1264-1281.e20
pubmed: 33091337
Nat Immunol. 2022 Mar;23(3):446-457
pubmed: 35177831
Nature. 2017 Jul 6;547(7661):94-98
pubmed: 28636589
Clin Immunol. 2010 Jun;135(3):466-75
pubmed: 20181533
Nat Med. 2019 Aug;25(8):1243-1250
pubmed: 31332390
J Immunol. 2017 Oct 1;199(7):2203-2213
pubmed: 28923982
Front Immunol. 2021 Jul 20;12:715234
pubmed: 34354714
N Engl J Med. 2022 Jul 21;387(3):217-226
pubmed: 35857659
Nat Methods. 2015 May;12(5):380-1
pubmed: 25924071
Immunol Rev. 2012 Nov;250(1):10-31
pubmed: 23046120
PLoS Comput Biol. 2015 Nov 25;11(11):e1004503
pubmed: 26606115
J Clin Oncol. 2017 Oct 10;35(29):3322-3329
pubmed: 28809608
Nat Biotechnol. 2020 Oct;38(10):1194-1202
pubmed: 32341563
Nature. 2023 Mar;615(7953):687-696
pubmed: 36356599
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
Semin Immunol. 2007 Aug;19(4):216-24
pubmed: 17398114
Nat Med. 2018 Jun;24(6):724-730
pubmed: 29867227
PLoS Comput Biol. 2021 Jan 19;17(1):e1008486
pubmed: 33465095
Cell. 2018 Sep 20;175(1):85-100.e23
pubmed: 30173916
Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):E10409-E10417
pubmed: 29138313
FEBS Open Bio. 2019 Aug;9(8):1450-1459
pubmed: 31237075
Front Mol Biosci. 2022 Aug 19;9:903065
pubmed: 36060249
Int J Cancer. 2019 Feb 15;144(4):818-827
pubmed: 30151844
Bioinformatics. 2017 Sep 15;33(18):2938-2940
pubmed: 28645171
Science. 2006 Oct 6;314(5796):126-9
pubmed: 16946036
Nat Rev Immunol. 2012 Sep;12(9):669-77
pubmed: 22918468
J Immunol. 2005 Mar 1;174(5):2563-72
pubmed: 15728462
Cancers (Basel). 2022 Mar 31;14(7):
pubmed: 35406543
Cancer Immunol Res. 2017 Feb;5(2):148-156
pubmed: 28039161
EBioMedicine. 2019 Sep;47:414-426
pubmed: 31477563
Nat Rev Immunol. 2018 Jul;18(7):467-478
pubmed: 29636542
Int Immunol. 2004 Mar;16(3):423-31
pubmed: 14978016
Cancer Biol Med. 2019 May;16(2):350-360
pubmed: 31516755

Auteurs

Andrea Aran (A)

Immunology Unit, Department of Cell Biology, Physiology, and Immunology, Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.

Gonzalo Lázaro (G)

Immunology Unit, Department of Cell Biology, Physiology, and Immunology, Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.

Vicente Marco (V)

Pathology, Hospital Quironsalud Barcelona, Barcelona, Spain.

Elisa Molina (E)

Immunology Unit, Department of Cell Biology, Physiology, and Immunology, Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.

Ferran Abancó (F)

Immunology Unit, Department of Cell Biology, Physiology, and Immunology, Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.

Vicente Peg (V)

Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Department of Morphological Sciences, Universidad Autónoma de Barcelona, Bellaterra, Spain.
Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain.

María Gión (M)

Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain.

Laia Garrigós (L)

International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona, Spain.

José Pérez-García (J)

International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona, Spain.
Medical Scientia Innovation Research (MedSIR), Barcelona, Spain.

Javier Cortés (J)

International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona, Spain.
Medical Scientia Innovation Research (MedSIR), Barcelona, Spain.
Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.

Mercè Martí (M)

Immunology Unit, Department of Cell Biology, Physiology, and Immunology, Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain.
Biosensing and Bioanalysis Group, Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH